We explore a range of difficult-to-treat cancers where transformative solutions can’t wait, and our passion extends to supporting people living with cancer and the loved ones who care for them.



    The most common form of thyroid cancer is DTC, which comprises more than 90% of all thyroid cancers. Although it is often treatable, unmet needs remain among those with metastatic disease, particularly those with radioactive iodine (RAI)-refractory DTC, for which the five-year survival rate is 19%.


    EC is the most common type of uterine cancer, accounting for more than 90% of cases. Racial disparities are pronounced among those with endometrial cancer. Specifically, Black patients are more likely to have advanced stage or unstaged disease, and experience a lower 5-year survival rate than white patients.


    Head and neck cancer (HNC) broadly refers to tumors that occur in different areas of the mouth, lips, tongue, nasal cavity, larynx (voice box), throat, sinuses and lymph nodes. HNC accounts for nearly 4% of cancers in the U.S., with an estimated 71,100 new cases expected to be diagnosed in 2024.


    In 2024, kidney cancer was the eighth most common cancer in men and the twelfth most common in women. The most common type, making up 90% of kidney cancers, is renal cell carcinoma (RCC). As many as 40% of patients with localized disease experience disease recurrence after primary surgical treatment, and 20% to 30% of patients have metastatic RCC at diagnosis.


    The most common type of liver cancer is hepatocellular carcinoma (HCC), which makes up approximately 90% of liver cancer cases. The incidence of liver cancer rates tripled over the past four decades. Although survival rates have increased in recent years, high unmet needs remain in liver cancer, with a 5-year survival rate of only 21%.


    Breast cancer is estimated to be the most common cancer diagnosis among women in the United States, with invasive female breast cancer rates increasing by ~0.5% per year since the mid-2000s. Approximately 6% of women and 9% of men with breast cancer will have MBC at the time of diagnosis, and an estimated 20-30% of women with early-stage breast cancer will go on to develop metastatic disease.


    Here are some of the other cancers we’re exploring through our research:

    Esophageal cancer

    This cancer makes up about 1% of all cancers diagnosed in the United States and is far more common among men than women. The chance of getting esophageal cancer increases with age—fewer than 15% of cases are found in people under the age of 55. It is estimated that about 22,370 new esophageal cancer cases will be diagnosed in 2024.

    Fallopian tube cancer

    This type of cancer develops in the fallopian tubes that connect the ovaries to the uterus. It is very rare, accounting for 1%-2% of all gynecologic cancers. Approximately 300-400 women are diagnosed with the condition each year.

    Gastric cancer

    Also known as stomach cancer, gastric cancer starts in the cells lining the stomach. The 5-year survival rate for people with localized stomach cancer is 75%, but for those whose cancer has metastasized, it drops significantly to only 7%.

    Non-small cell lung cancer (NSCLC)

    Lung cancer is the leading cause of cancer-related deaths in the United States, with 125,070 deaths estimated in 2024. NSCLC accounts for 80% of all lung cancer cases. The 5-year survival rates among those with lung cancer remain low, highlighting a need to expand and improve therapeutic options.

    Ovarian cancer

    Ovarian cancer is the second most common gynecologic cancer in the U.S., and causes more deaths than any other cancer of the female reproductive system. Ovarian cancer is frequently diagnosed when the disease is already advanced, with most patients facing a poor prognosis because of high rates of recurrence and subsequent development of chemoresistance. It is estimated that 19,680 women will be diagnosed and 12,740 will die from ovarian cancer in 2024. However, ovarian cancer diagnoses and deaths have been declining over the last two decades.

    Peritoneal cancer

    Peritoneal cancers can start in the peritoneum (the lining of the abdominal cavity) but are often cancers that have spread to the peritoneum from ovarian cancer, primary colorectal cancer, appendiceal cancer, mesothelioma or pseudomyxoma peritonei. This spreading of cancerous cells represents an advanced stage of cancer with a poor prognosis, which makes early diagnosis and prompt management essential.

    Soft tissue sarcoma

    This is a type of cancer that starts in the soft tissues of the body—including fat (liposarcoma), muscle (such as leiomyosarcoma, which forms in the smooth muscles), nerves, blood vessels and tissues around the joints. There are more than 50 different types of soft tissue sarcoma. These cancers can be hard to diagnose, creating large unmet needs for therapeutic options and more awareness.